Key result
NSAID exposure prior to major upper gastrointestinal bleeding did not significantly alter clinical presentation, with 40% of both NSAID users and nonusers experiencing no preceding symptoms.
Why the study?
Does NSAID exposure alter the clinical presentation of major upper gastrointestinal bleeding in patients with a first episode of major UGIB?
Case-Control
Yes
Does NSAID exposure alter the clinical presentation of major upper gastrointestinal bleeding in patients with a first episode of major UGIB?
The clinical presentation of major upper gastrointestinal bleeding does not differ significantly between NSAID users and nonusers, and preceding symptoms are frequently absent in both groups.
No takes yet. Share an insight, caveat, or question.
Silent major UGIB presentation is common irrespective of NSAID use; leaves open symptom-masking effects and needs prospective confirmation.
András László (1998) conducted a case-control in Major upper gastrointestinal bleeding (UGIB). Nonsteroidal antiinflammatory drugs (NSAID) vs. No NSAID exposure during the week before the onset of bleeding was evaluated on Clinical features of major upper gastrointestinal bleeding (including clinical appearance, site of bleeding, preceding symptoms, and requirement for transfusion/surgery). NSAID exposure prior to major upper gastrointestinal bleeding did not significantly alter clinical presentation, with 40% of both NSAID users and nonusers experiencing no preceding symptoms.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: